Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Insights into clonal and CBC changes at disease evolution among ccus patients

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, David Viswanatha, James Foran, Talha Badar, Cecilia Arana Yi, Yael Kusne, Antoine Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, William Hogan, Abhishek Mangaonkar, Mithun Shah, Hassan Alkhateeb, Mrinal Patnaik, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 5621.

https://doi.org/10.1182/blood-2025-5621

Published: 2025

Journal Articles

Clinicopathologic features of myeloid neoplasms and pre-neoplasms with isolated ZRSR2 mutations

Alma Oskarsdottir, Rong He, Jennifer Jiang, Mahmoud Yacout, Patricia Greipp, Mithun Shah, Hassan Alkhateeb, David Viswanatha, Fiona Craig, Katalin Kelemen, Aref Al-Kali, Dragan Jevremovic

Blood (2025) 146 (Supplement 1): 7394.

https://doi.org/10.1182/blood-2025-7394

Published: 2025

Journal Articles

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Blood (2025) 146 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2025-7045

Published: 2025

Journal Articles

Molecular association with elevated LDH levels in patients with AML

Oudai Alkabbani, Yazan Jabban, Rong He, David Viswanatha, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, Antoine Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, William Hogan, Abhishek Mangaonkar, Hassan Alkhateeb, Mrinal Patnaik, Mithun Shah, Kebede Begna, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2025-7039

Published: 2025

Journal Articles

Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms

Blood (2025) 146 (Supplement 1): 2586.

https://doi.org/10.1182/blood-2025-2586

Published: 2025

Journal Articles

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Blood (2025) 146 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2025-7370

Published: 2025

Journal Articles

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Tariq Kewan, Oudai Alkabbani, Rong He, Dragan Jevremovic, Patricia Greipp, Antoine Saliba, Aasiya Matin, Mehrdad Hefazi Torghabeh, Abhishek Mangaonkar, Naseema Gangat, William Hogan, Mrinal Patnaik, Hassan Alkhateeb, Cecilia Arana Yi, James Foran, Mark Litzow, Mithun Shah, Kebede Begna, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 996.

https://doi.org/10.1182/blood-2025-996

Published: 2025

Journal Articles

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, Aasiya Matin, William J. Hogan, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Mithun V Shah, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 6700.

https://doi.org/10.1182/blood-2024-201128

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, Rong He, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Abhishek A. Mangaonkar, Mithun V Shah, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2024-208957

Published: 2024

Journal Articles

Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Jessica Lewis-Gonzalez, Jonathon Cordova, Huining Kang, Cecilia Y. Arana Yi, Ahmed Ibrahim, Patricia Greipp, Anand Ashwin Patel, Muriel Battaglia, Anthony J. Perissinotti, Bernard Lawrence Marini, Martina Fraga, Dale Bixby, Kristen M. Pettit, Patrick W. Burke, Charles Foucar

Blood (2024) 144 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2024-212205

Published: 2024

Journal Articles

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Blood (2024) 144 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2024-203517

Published: 2024

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Blood (2023) 142 (Supplement 1): 656.

https://doi.org/10.1182/blood-2023-178150

Published: 2023

Journal Articles

IPSS-M - Use for Predicting Survival and Progression in Patients with Ccus - a Retrospective Multi-Institutional Study

Ahmad Nanaa, Aref Al-Kali, Dragan Jevremovic, Phuong L. Nguyen, Patricia Greipp, Rong He, Mrinal M. Patnaik, Abhishek A Mangaonkar, Hassan Alkhateeb, Julia Anderson, Weina Chen, Olga Weinberg, Stephen Chung, Yazan F. Madanat

Blood (2023) 142 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2023-191048

Published: 2023

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Mark Gurney, Ismahene Chekkaf, Rong He, David S. Viswanatha, Patricia Greipp, Abhishek A. Mangaonkar, Kebede Begna, Naseema Gangat, Mrinal M. Patnaik, Mark R. Litzow, James M. Foran, Talha Badar, Mithun V. Shah, Hassan B. Alkhateeb, Aref Al-Kali

Blood (2022) 140 (Supplement 1): 6912–6914.

https://doi.org/10.1182/blood-2022-170641

Published: 2022

Journal Articles

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 12353–12354.

https://doi.org/10.1182/blood-2022-155561

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Insights into clonal and CBC changes at disease evolution among ccus patients

Clinicopathologic features of myeloid neoplasms and pre-neoplasms with isolated ZRSR2 mutations

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Molecular association with elevated LDH levels in patients with AML

Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

IPSS-M - Use for Predicting Survival and Progression in Patients with Ccus - a Retrospective Multi-Institutional Study

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only